Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brinzolamide after macular hole repair
ACTRN12620001230943Phase 3Withdrawn
- Sponsor
- Stephen Guest
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of brinzolamide in Full Thickness Macular Hole (FTMH) (2 arms), sponsored by Stephen Guest. Primary endpoints: Change in LogMAR vision in operated eye and Total resolution of subretinal fluid by optical coherence tomography. Planned start Feb 2021; status: withdrawn.
02
Drugs
brinzolamide
03
Conditions
Full Thickness Macular Hole (FTMH)
Beyond the preview
Go deeper on ACTRN12620001230943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620001230943.